Hologic's (HOLX) "Equal Weight" Rating Reiterated at Stephens

Key Points

• Hologic's stock rating was reiterated as "equal weight" by Stephens, with a new target price of $76.00, indicating a potential upside of 2.75% from its previous close.
• The company reported an earnings per share (EPS) of $1.08 for the last quarter, slightly exceeding analyst expectations, with a revenue of $1.02 billion, marking a year-over-year growth of 1.2%.
• In insider trading, CEO Stephen P. Macmillan sold 138,358 shares at an average price of $66.97, decreasing his ownership by 10.08% but still retaining over $82 million in company stock.

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "equal weight" rating reiterated by Stephens in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $76.00 target price on the medical equipment provider's stock, down from their prior target price of $78.00. Stephens' price objective would indicate a potential upside of 2.75% from the company's previous close.

Several other brokerages have also recently commented on HOLX. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $78.00 target price on shares of Hologic in a report on Wednesday. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and increased their price target for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Finally, BTIG Research reissued a "neutral" rating on shares of Hologic in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $79.00.

Hologic Stock Performance

Hologic stock traded down $0.02 during trading hours on Wednesday, hitting $73.97. The company had a trading volume of 4,553,603 shares, compared to its average volume of 2,720,524. The firm has a market cap of $16.45 billion, a PE ratio of 30.69, a PEG ratio of 2.47 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic has a one year low of $51.90 and a one year high of $84.39. The firm has a 50-day moving average of $67.31 and a 200 day moving average of $63.69.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the firm earned $1.06 earnings per share. The business's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.88% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HOLX. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Hologic during the first quarter valued at about $399,000. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Hologic by 1.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock valued at $1,980,000 after buying an additional 528 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Hologic by 10.4% during the first quarter. Oppenheimer & Co. Inc. now owns 23,433 shares of the medical equipment provider's stock valued at $1,447,000 after buying an additional 2,208 shares during the last quarter. Asset Management One Co. Ltd. grew its holdings in shares of Hologic by 4.2% during the first quarter. Asset Management One Co. Ltd. now owns 151,172 shares of the medical equipment provider's stock valued at $9,338,000 after buying an additional 6,144 shares during the last quarter. Finally, Lecap Asset Management Ltd. grew its holdings in shares of Hologic by 30.0% during the first quarter. Lecap Asset Management Ltd. now owns 65,592 shares of the medical equipment provider's stock valued at $4,052,000 after buying an additional 15,131 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.